Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03700502
Other study ID # 201605027
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 5, 2016
Est. completion date November 2018

Study information

Verified date March 2018
Source Nanjing First Hospital, Nanjing Medical University
Contact Jin Dan Wu, master
Phone 0086-18951670336
Email wujindandan@sina.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Patients with painful diabetic neuropathy (PDN) often combine with anxiety and depression. However, the pathogenesis of PDN is unclear, especially the mechanism associated with central nervous system. The investigators used fraction Amplitude of Low Frequency Fluctuation (fALFF) and Regional Homogeneity (ReHo) of resting-state functional Magnetic Resonance Imaging (rs-fMRI) to explore the brain activity in patients with PDN in order to study the central mechanism.The investigators evaluated the symptoms, signs and mental conditions of patients with PDN and non-pain neuropathy. The brain Blood Oxygen Level Dependent (BOLD) fMRI scan was performed in patients together with some gender and age matched healthy controls. Maybe this study can find that patients with PDN have abnormal brain activity, indicating central nervous system may contribute to painful diabetic neuropathy.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date November 2018
Est. primary completion date November 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Voluntary participation and signing informed consent

- 18 to 60 years old with junior high school education or above

- meeting the 1999 WHO type 2 diabetes diagnostic criteria: having symptoms of diabetes (polydipsia, polyphagia, polyuria and unexplained weight loss) plus one of the following 3 items: (1) random blood glucose more than 11.1 mmol/L; (2) fasting blood glucose more than 7 mmol/L; (3) after 2 hours glucose load, the blood sugar more than 11.1 mmol/L

- The diagnosis of diabetic peripheral neuropathy (at the same time meets the following three items, of which painful neuropathy patients have pain symptom): (1) neuropathy occurs not earlier than the diagnosis of diabetes; (2) having clinical manifestations of pain, numbness, and abnormal sensation; (3) any abnormality in the following 5 examinations: ankle reflex, vibratory sensation, pressure sensation, temperature sensation, and acupuncture pain

Exclusion Criteria:

- left-hand writers

- neuropathy caused by other causes, such as cervical spondylosis, cerebral infarction, Green Barre syndrome; severe arteriovenous disease; neurotoxic changes caused by drugs and renal insufficiency

- patients with severe cerebral vascular disease

- diagnosed mental disorders such as depression, anxiety and Alzheimer's disease

- patients who can`t accept head magnetic resonance imaging, such as those with metal (stents, metal dentures, internal fixation plates, etc.), and claustrophobic space phobias

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
resting-state functional Magnetic Resonance Imaging
The investigators used fraction Amplitude of Low Frequency Fluctuation (fALFF) and Regional Homogeneity (ReHo) of resting-state functional Magnetic Resonance Imaging (rs-fMRI) to explore the brain activity in patients with PDN in order to study the central mechanism. The investigators also evaluated the symptoms, signs and mental conditions of the patients.

Locations

Country Name City State
China the first hospital of Nanjing Nanjing Jiangsu

Sponsors (2)

Lead Sponsor Collaborator
Nanjing First Hospital, Nanjing Medical University Jiangsu Province Nanjing Brain Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary resting-state functional Magnetic Resonance Imaging collect and analyze the data of brain fMRI one or two years
See also
  Status Clinical Trial Phase
Recruiting NCT04699734 - Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy N/A
Recruiting NCT05476276 - EPPIC-Net: Platform Protocol to Assess Treatments for Painful Diabetic Peripheral Neuropathy Phase 2
Recruiting NCT05480228 - EPPIC-Net: Novaremed Painful Diabetic Peripheral Neuropathy ISA Phase 2
Unknown status NCT01125215 - Capsaicin Nanoparticle in Patient With Painful Diabetic Neuropathy Phase 2/Phase 3
Not yet recruiting NCT05937984 - Treatment for Painful Diabetic Neuropathy N/A
Recruiting NCT05080530 - Vitamin D and Painful Diabetic Neuropathy N/A
Completed NCT04005287 - A 24-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Peripheral Neuropathy Phase 2
Recruiting NCT03331614 - An Evaluation of an SCCD on the Symptomatology of Painful DPN N/A
Recruiting NCT03700528 - The Development of Contextual Cognitive Behavioural Approach to PDN N/A
Recruiting NCT04689958 - The Benefits of Vitamin D 5000 IU as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient Phase 2/Phase 3
Recruiting NCT04689984 - The Benefits of Astaxanthin as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient Phase 2/Phase 3
Recruiting NCT04689971 - The Benefits of Vitamin B Combination as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient Phase 2/Phase 3
Completed NCT03749642 - Trazodone/Gabapentin Fixed Dose Combination Products in Painful Diabetic Neuropathy Phase 2
Not yet recruiting NCT04087941 - Efficacy and Safety of VM202 in Painful Diabetic Peripheral Neuropathy -The HOPES Trial Phase 2
Terminated NCT01129960 - Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain Phase 3
Terminated NCT01056315 - A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y Phase 2
Completed NCT00980746 - Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy Phase 2
Completed NCT04786340 - A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy Phase 2
Completed NCT03769675 - Quantitative Assessment of Painful Diabetic Peripheral Neuropathy After High Frequency Spinal Cord Stimulation N/A
Completed NCT03755934 - Efficacy and Safety of MEDI7352 in Subjects With Painful Diabetic Neuropathy Phase 2